chang tp
number share mn
price month
preliminari announc agit
event march market close otsuka releas preliminari
result first studi phase trial investig efficaci
safeti toler novel compound agit
accompani alzheim diseas compound develop
announc includ detail reveal mix result one
improv versu placebo primari endpoint cohen-mansfield
agit inventori cmai scale evalu frequenc
agit symptom dose numer improv
differ placebo group statist signific
phase trial on-going schedul conclud around
decemb around june expect result next
studi determin valu
implic monitor impact otsuka share price
interest announc come immedi eisai/biogen
effect termin develop aducanumab alzheim
diseas phase led signific fall share price
compani expect risk write-down
realiz stage see risk part pictur due high level
interest alzheim treatment
price rel chart measur perform
topix close
spot exchang rate
valuat metric
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
issuanc retir stock
net chang cash
number share mn
compani mention price
